Metastatic disease from renal cell carcinoma

A Phase I/II clinical trial was conducted in 10 patients with metastatic tumors (renal cell carcinoma, colon carcinoma, melanoma). Tumor material from each patient was isolated, and the cells were ex vivo double-transfected using MIDGE vectors encoding GM-GSF and IL-7. Thereafter, the cells were irradiated and dSLIM added. This autologous therapeutic agent was injected into the patients four times at intervals of 14 days. At the injection site, the APCs were in contact with TAAs and immunomodulating molecules, and this led to a tumor-specific immune response. In total, 50% of the patients responded clinically to the therapy, exhibiting complete or partial response, or stable disease (Fig. 7.14) [60]. 

---